Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Intellia Therapeutics to Present at February Healthcare Investor Conferences


Posted on: 31 Jan 18

CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming healthcare conferences in February:


Wednesday, February 14, 2018

Leerink Partners 7th Annual Healthcare Conference

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences

Location: New York, New York

Presentation Time: 1:00pm EST


Tuesday, February 27, 2018

Credit Suisse 2018 Global Healthcare Conference

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences

Location: London, United Kingdom

One-on-one meetings only


A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets

Investor Contact: Media Contact:
Lindsey TrickettJennifer Mound Smoter
Vice President, Investor Relations                                                                                                                                 Senior Vice President, External Affairs & 
+1 857-285-6211Communications
lindsey.trickett@intelliatx.com +1 857-706-1071
 jenn.smoter@intelliatx.com

                          








 

GlobeNewswire
globenewswire.com

Last updated on: 01/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.